|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenue
|
|
$7.3m
|
$9.7m
|
$9.0m
|
$9.1m
|
$28.2m
|
$87.5m
|
$179.5m
|
$242.7m
|
|
Gross profit
|
|
$5.7m
|
$13.9m
|
$16.6m
|
$21.2m
|
$65.3m
|
$154.1m
|
$262.1m
|
$362.8m
|
|
Selling, general and administrative
|
|
$12.3m
|
$23.6m
|
$24.2m
|
$38.3m
|
$69.9m
|
$119.6m
|
$168.6m
|
$185.2m
|
|
Total operating expenses
|
|
$26.0m
|
$43.5m
|
$43.0m
|
$60.6m
|
$96.7m
|
$182.8m
|
$224.6m
|
$254.2m
|
|
Research, development and clinical trials
|
|
$13.7m
|
$19.9m
|
$18.8m
|
$22.3m
|
$26.8m
|
$36.1m
|
$56.0m
|
$69.1m
|
|
Income (loss) from operations
|
|
($20.2m)
|
($29.6m)
|
($26.4m)
|
($39.4m)
|
($31.4m)
|
($28.7m)
|
$37.5m
|
$108.6m
|
|
Income (loss) before income taxes
|
|
—
|
—
|
($28.7m)
|
($44.2m)
|
($36.2m)
|
($26.7m)
|
$35.8m
|
$107.5m
|
|
(Provision) benefit for income taxes
|
|
—
|
—
|
—
|
($36k)
|
($66k)
|
$1.6m
|
$316k
|
$82.8m
|
|
Net income (loss)
|
|
($23.8m)
|
($33.5m)
|
($28.7m)
|
($44.2m)
|
($36.2m)
|
($25.0m)
|
$35.5m
|
$190.3m
|
|
Net income (loss) per share, basic
|
|
—
|
—
|
($1)
|
($2)
|
($1)
|
($1)
|
$1
|
$6
|
|
Net income (loss) per share, diluted
|
|
($17)
|
($2)
|
($1)
|
($2)
|
($1)
|
($1)
|
$1
|
$5
|
|
Weighted average common shares outstanding, basic
|
|
—
|
—
|
24.7m
|
27.6m
|
29.6m
|
32.5m
|
33.2m
|
34.0m
|
|
Weighted average common shares outstanding, diluted
|
|
—
|
—
|
24.7m
|
27.6m
|
29.6m
|
32.5m
|
35.2m
|
40.5m
|
|
Acquired in-process research and development expenses
|
|
—
|
—
|
—
|
—
|
—
|
$27.2m
|
—
|
—
|
|
Interest expense
|
|
($2.7m)
|
($4.4m)
|
($4.0m)
|
($3.9m)
|
($3.7m)
|
($10.8m)
|
($14.4m)
|
($13.8m)
|
|
Interest income and other income (expense), net
|
|
—
|
—
|
—
|
—
|
($1.0m)
|
$12.8m
|
$12.7m
|
$12.7m
|
|
Total other income (expense), net
|
|
($3.5m)
|
($3.9m)
|
($2.3m)
|
($4.8m)
|
($4.7m)
|
$2.1m
|
($1.7m)
|
($1.1m)
|